Bristol-Myers Squibb

Diversified pharma

BMY · NYSE · United States

Share price · BMY

$59.56-6.49 (-9.83%) 3M

close as of 2026-11-18 · 24h delayed · vol 11.1M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BMY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 12 Oct 2026-2.6%
  2. 5 Oct 2026-3.8%
  3. 5 Aug 2026-3.4%
  4. 30 Jul 2026+2.8%
  5. 15 Jul 2026+3.1%
  6. 13 Jul 2026+3.1%
  7. 1 Jul 2026-2.0%
  8. 8 Jun 2026-3.0%
  9. 1 Jun 2026-3.9%
  10. 1 May 2026-3.9%

Share of unusual movement by asset

For each asset, the share of BMY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Xanomeline/trospium chloride (Cobenfy)
events and moves
6shown from 8 days
Repotrectinib
events and moves
6shown from 8 days
Mavacamten (Camzyos)
events and moves
5shown from 8 days
Iberdomide (Zenbexus)
events and moves
5shown from 8 days
Afimetoran
events and moves
4shown from 8 days
Mezigdomide
events and moves
2shown from 8 days
deucravacitinib (Sotyktu)
events and moves
2shown from 8 days
Opdivo Qvantig
events and moves
2shown from 8 days
Izalontamab brengitecan
events and moves
2shown from 8 days
Obexelimab
events and moves
2shown from 8 days
Arlocabtagene autoleucel
events and moves
1shown from 8 days
ozanimod (Zeposia)
events and moves
1shown from 8 days
Nivolumab
events and moves
1shown from 8 days
Pumitamig
events and moves
1shown from 8 days
Relatlimab
events and moves
1shown from 8 days
Navlimetostat
events and moves
1shown from 8 days
Actinium (225Ac) oxodotreotide
events and moves
1shown from 8 days
Adagrasib (Krazati)
events and moves
1shown from 8 days
Romidepsin
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—9%
Other company news (earnings, financing, releases naming no asset)—24%
Sessions with no dated event—67%

Assets

(61 total)
61Total Assets
23Approved
8Phase 3 / Filed
30Phase 1–2 / Early
42Diseases
Quick filter:
Showing 61 of 61 assets
Target & Modality
Abatacept(Orencia)
Approved
CD80/CD86 (CTLA-4-Ig) · Selective T Cell Costimulation Modulator · CD80/CD86 (B7-1/B7-2) on antigen-presenting cellsProtein / enzyme therapeutic
Psoriatic ArthritisRheumatoid Arthritis
Adagrasib(Krazati)
Approved
KRAS G12CSmall molecule
Non-Small Cell Lung Cancer
Approved
DNMT1 (DNA methyltransferase 1)Small molecule
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Approved
DNMT1 (DNA methyltransferase 1)Small molecule
Acute Myeloid Leukemia
Approved
TYK2Small molecule
Psoriatic ArthritisPsoriasisSystemic Lupus ErythematosusSjögren's Disease
Approved
SLAMF7 (CS1/CD319)Monoclonal antibody
Multiple Myeloma
Enasidenib(Idhifa)
Approved
IDH2Small molecule
Acute Myeloid Leukemia
Approved
HBV polymerase (reverse transcriptase)Small molecule
Chronic Hepatitis B
Iberdomide(Zenbexus)
Approved
Cereblon E3 ubiquitin-ligaseSmall molecule
Multiple Myeloma
Approved
BCMACell therapy
Multiple Myeloma
Approved
CTLA-4 antagonistMonoclonal antibody
Non-Small Cell Lung CancerHepatocellular CarcinomaColorectal CancerBladder / Urothelial CancerRenal Cell CarcinomaMelanomaEsophageal Cancer
Urothelial Carcinoma, Metastatic Colorectal Cancer, Esophageal Squamous Cell Carcinoma, Cutaneous Melanoma, Advanced Metastatic Colorectal Cancer
Approved
Cereblon E3 ubiquitin-ligase · Thalidomide AnalogSmall molecule
Multiple MyelomaFollicular LymphomaMyelodysplastic SyndromesMantle Cell Lymphoma
Mavacamten(Camzyos)
Approved
Cardiac myosin (inhibitor)Small molecule
Heart FailureHypertrophic Cardiomyopathy
Approved
MicrotubulesSmall molecule
Non-Small Cell Lung CancerBreast Cancer
HR+/HER2- Metastatic Breast Cancer
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung CancerHepatocellular CarcinomaColorectal CancerGastric CancerHead and Neck Squamous Cell CarcinomaBladder / Urothelial CancerRenal Cell CarcinomaMelanomaEsophageal Cancer
Urothelial Carcinoma, Metastatic Colorectal Cancer, Esophageal Squamous Cell Carcinoma, Advanced Metastatic Colorectal Cancer

Upcoming events

(145 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (22)
November 2026 (3)
Izalontamab brengitecanPhase 3Nasopharyngeal Carcinoma
Est. primary completion 2026-11 · NCT06118333 · CT.gov ↗
What to watch
Est. primary completion 2026-11-24 · NCT06585787 · CT.gov ↗
What to watch
Mezigdomide + ElotuzumabPhase 1/2Multiple Myeloma
Est. primary completion 2026-11-30 · NCT03989414 · CT.gov ↗
What to watch
December 2026 (19)
Izalontamab brengitecanPhase 1/2Gynecological Malignant Tumor, Solid Tumor
Est. primary completion 2026-12 · NCT05803018 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Urinary System Tumor, Solid Tumor
Est. primary completion 2026-12 · NCT05785039 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Small Cell Lung Cancer
Est. primary completion 2026-12 · NCT05924841 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
Est. primary completion 2026-12 · NCT05956587 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Urothelial Carcinoma, Solid Tumor
Est. primary completion 2026-12 · NCT05965856 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Cervical Cancer
Est. primary completion 2026-12 · NCT05990803 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Head and Neck Squamous Cell Carcinoma
Est. primary completion 2026-12 · NCT06006169 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Esophageal Cancer, Gastric Cancer, Colorectal Cancer
Est. primary completion 2026-12 · NCT06008054 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Breast Cancer
Est. primary completion 2026-12 · NCT06042894 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Urothelial Carcinoma
Est. primary completion 2026-12 · NCT06405425 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Extensive-stage Small-cell Lung Cancer
Est. primary completion 2026-12 · NCT06437509 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Triple-negative Breast Cancer
Est. primary completion 2026-12 · NCT06471205 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Non-small Cell Lung Cancer
Est. primary completion 2026-12 · NCT06382129 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Small Cell Lung Cancer
Est. primary completion 2026-12 · NCT06500026 · CT.gov ↗
What to watch
Actinium (225Ac) oxodotreotidePhase 3GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors …
Est. primary completion 2026-12 · NCT05477576 · CT.gov ↗
What to watch
MilvexianPhase 3Atrial Fibrillation
Est. primary completion 2026-12-08 · NCT05757869 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3Psychosis Associated With Alzheimer's Disease
Est. primary completion 2026-12-09 · NCT06126224 · CT.gov ↗
What to watch
DelocamtenPhase 2Heart Failure
Est. primary completion 2026-12-14 · NCT06122779 · CT.gov ↗
What to watch
MoponetugPhase 2Alzheimer Disease, Early Onset
Est. primary completion 2026-12-17 · NCT06268886 · CT.gov ↗
What to watch
2027 (36)
January 2027 (2)
PumitamigPhase 2Neuroendocrine Neoplasm
Est. primary completion 2027-01-01 · NCT05879055 · CT.gov ↗
What to watch
MezigdomidePhase 3Relapsed or Refractory Multiple Myeloma
Est. primary completion 2027-01-10 · NCT05519085 · CT.gov ↗
What to watch
February 2027 (2)
Nivolumab + IpilimumabPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2027-02-05 · NCT06946797 · CT.gov ↗
What to watch
RepotrectinibPhase 3Carcinoma, Non-Small-Cell Lung
Est. primary completion 2027-02-16 · NCT06140836 · CT.gov ↗
What to watch
March 2027 (1)
Nivolumab + IpilimumabPhase 3Renal Cell Carcinoma
Est. primary completion 2027-03-11 · NCT03873402 · CT.gov ↗
What to watch
April 2027 (1)
GolcadomidePhase 1/2Lymphoma, Non-Hodgkin
Est. primary completion 2027-04-07 · NCT03930953 · CT.gov ↗
What to watch
May 2027 (8)
PumitamigPhase 2CRC (Colorectal Cancer)
Est. primary completion 2027-05 · NCT07133750 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Renal Cancer
Est. primary completion 2027-05 · NCT06962787 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Advanced Biliary Tract Cancer
Est. primary completion 2027-05 · NCT06978114 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Advanced Hepatocellular Carcinoma
Est. primary completion 2027-05 · NCT06986785 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Cervical Cancer, Endometrial Cancer
Est. primary completion 2027-05 · NCT07054567 · CT.gov ↗
What to watch
PumitamigPhase 3SCLC
Est. primary completion 2027-05 · NCT06616532 · CT.gov ↗
What to watch
IrafamdastatPhase 2Multiple Sclerosis Spasticity
Est. primary completion 2027-05-26 · NCT06782490 · CT.gov ↗
What to watch
MezigdomidePhase 1/2Multiple Myeloma
Est. primary completion 2027-05-31 · NCT06988488 · CT.gov ↗
What to watch
June 2027 (8)
PumitamigPhase 2Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Est. primary completion 2027-06 · NCT06449209 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Non-small Cell Lung Cancer
Est. primary completion 2027-06 · NCT06498986 · CT.gov ↗
What to watch
Est. primary completion 2027-06 · NCT06787664 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Head and Neck Squamous Cell Carcinoma
Est. primary completion 2027-06 · NCT06437522 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor
Est. primary completion 2027-06 · NCT06475300 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Urothelial Carcinoma
Est. primary completion 2027-06 · NCT06857175 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Est. primary completion 2027-06 · NCT06994195 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3Mania, Bipolar Disorder
Est. primary completion 2027-06-28 · NCT07140913 · CT.gov ↗
What to watch
July 2027 (2)
Izalontamab brengitecanPhase 2Non-small Cell Lung Cancer
Est. primary completion 2027-07 · NCT05880706 · CT.gov ↗
What to watch
PumitamigPhase 3Triple Negative Breast Cancer(TNBC)
Est. primary completion 2027-07 · NCT06419621 · CT.gov ↗
What to watch
August 2027 (2)
GolcadomidePhase 3Large B-cell Lymphoma
Est. primary completion 2027-08-09 · NCT06356129 · CT.gov ↗
What to watch
Nivolumab + AtigotatugPhase 3Extensive-Stage Small Cell Lung Cancer
Est. primary completion 2027-08-17 · NCT06646276 · CT.gov ↗
What to watch
September 2027 (2)
DanicamtivPhase 2/3Symptomatic Genetic Dilated Cardiomyopathy
Est. primary completion 2027-09 · NCT07210723 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3Psychosis Associated With Alzheimer's Disease
Est. primary completion 2027-09-07 · NCT05980949 · CT.gov ↗
What to watch
October 2027 (1)
GolcadomidePhase 1/2Relapsed/Refractory Non-Hodgkin Lymphoma
Est. primary completion 2027-10-28 · NCT06090539 · CT.gov ↗
What to watch
November 2027 (3)
PumitamigPhase 1/2Advanced Solid Tumor
Est. primary completion 2027-11 · NCT07147348 · CT.gov ↗
What to watch
Iberdomide · ZenbexusPhase 3Multiple Myeloma
Est. primary completion 2027-11-16 · NCT04975997 · CT.gov ↗
What to watch
IrafamdastatPhase 2Agitation, Alzheimer Disease
Est. primary completion 2027-11-26 · NCT06808984 · CT.gov ↗
What to watch
December 2027 (4)
PumitamigPhase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Est. primary completion 2027-12 · NCT07255404 · CT.gov ↗
What to watch
ElotuzumabPhase 3Multiple Myeloma
Est. primary completion 2027-12 · NCT06158841 · CT.gov ↗
What to watch
Pomalidomide + Arlocabtagene autoleucelPhase 3Relapsed or Refractory Multiple Myeloma (RRMM)
Est. primary completion 2027-12-30 · NCT06615479 · CT.gov ↗
What to watch
Nivolumab + IpilimumabPhase 2Pan-tumor
Est. primary completion 2027-12-31 · NCT04566380 · CT.gov ↗
What to watch
2028 (36)
January 2028 (1)
PumitamigPhase 2Recurrent Glioblastoma
Est. primary completion 2028-01 · NCT07297212 · CT.gov ↗
What to watch
February 2028 (3)
NivolumabPhase 2Colorectal Cancer
Est. primary completion 2028-02-15 · NCT06948448 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3Alzheimer Disease, Psychosis
Est. primary completion 2028-02-21 · NCT06947941 · CT.gov ↗
What to watch
RepotrectinibPhase 1/2Locally Advanced Solid Tumors, Metastatic Solid Tumors
Est. primary completion 2028-02-29 · NCT03093116 · CT.gov ↗
What to watch
March 2028 (3)
PumitamigPhase 1/2Advanced Solid Tumor
Est. primary completion 2028-03 · NCT07070232 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2/3Breast Neoplasms
Est. primary completion 2028-03-13 · NCT06926868 · CT.gov ↗
What to watch
PumitamigPhase 2Early-Stage Non-Small Cell Lung Cancer
Est. primary completion 2028-03-15 · NCT07871214 · CT.gov ↗
What to watch
April 2028 (1)
GolcadomidePhase 3Follicular Lymphoma
Est. primary completion 2028-04-24 · NCT06911502 · CT.gov ↗
What to watch
May 2028 (1)
Zolacabtagene autoleucelPhase 2Lupus Erythematosus, Systemic, Lupus Nephritis
Est. primary completion 2028-05-17 · NCT07015983 · CT.gov ↗
What to watch
June 2028 (1)
Xanomeline/trospium chloride · CobenfyPhase 3Bipolar Disorder Type I With Mania
Est. primary completion 2028-06-13 · NCT06929273 · CT.gov ↗
What to watch
July 2028 (2)
Pumitamig + BMS-986517Phase 1/2Solid Tumours
Est. primary completion 2028-07-31 · NCT07160725 · CT.gov ↗
What to watch
Azacitidine (Onureg)Phase 2/3Myelodysplastic Syndromes
Est. primary completion 2028-07-31 · NCT05469737 · CT.gov ↗
What to watch
August 2028 (3)
PumitamigPhase 2Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
Est. primary completion 2028-08 · NCT06449222 · CT.gov ↗
What to watch
Est. primary completion 2028-08-15 · NCT07492680 · CT.gov ↗
What to watch
EzobresibPhase 1/2Myelofibrosis
Est. primary completion 2028-08-31 · NCT04817007 · CT.gov ↗
What to watch
September 2028 (5)
PumitamigPhase 1/2Advanced Lung Cancer
Est. primary completion 2028-09 · NCT06892548 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3Alzheimer's Disease
Est. primary completion 2028-09-11 · NCT06976203 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3Alzheimer's Disease
Est. primary completion 2028-09-11 · NCT06976216 · CT.gov ↗
What to watch
Pumitamig + ImzokitugPhase 2Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
Est. primary completion 2028-09-15 · NCT07680764 · CT.gov ↗
What to watch
Est. primary completion 2028-09-23 · NCT06882785 · CT.gov ↗
What to watch
October 2028 (3)
Actinium (225Ac) oxodotreotidePhase 1/2Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer …
Est. primary completion 2028-10 · NCT06590857 · CT.gov ↗
What to watch
PumitamigPhase 2Non-small Cell Lung Cancer
Est. primary completion 2028-10 · NCT06841055 · CT.gov ↗
What to watch
Nab-paclitaxel + BMS-986523Phase 1/2Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
Est. primary completion 2028-10-13 · NCT07223047 · CT.gov ↗
What to watch
November 2028 (5)
PumitamigPhase 1/2Non-small Cell Lung Cancer
Est. primary completion 2028-11 · NCT07111520 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3Alzheimer's Disease
Est. primary completion 2028-11-03 · NCT07011745 · CT.gov ↗
What to watch
EvifacotrepPhase 2Major Depressive Disorder
Est. primary completion 2028-11-06 · NCT07772531 · CT.gov ↗
What to watch
Zolacabtagene autoleucelPhase 3Systemic Sclerosis
Est. primary completion 2028-11-14 · NCT07335562 · CT.gov ↗
What to watch
Est. primary completion 2028-11-24 · NCT07011732 · CT.gov ↗
What to watch
December 2028 (8)
Izalontamab brengitecanPhase 2Non-small Cell Lung Cancer
Est. primary completion 2028-12 · NCT07827261 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2/3Castration-resistant Prostate Cancer
Est. primary completion 2028-12 · NCT07641855 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2/3Esophageal Squamous Cell Carcinoma
Est. primary completion 2028-12 · NCT07554456 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Non-small Cell Lung Cancer
Est. primary completion 2028-12 · NCT06838273 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Biliary Tract Cancer
Est. primary completion 2028-12 · NCT07582315 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Breast Cancer
Est. primary completion 2028-12 · NCT07648914 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2/3Non-Small Cell Lung Cancer
Est. primary completion 2028-12-15 · NCT07100080 · CT.gov ↗
What to watch
Izalontamab brengitecan + NavlimetostatPhase 2Carcinoma, Non-Small-Cell Lung
Est. primary completion 2028-12-29 · NCT06855771 · CT.gov ↗
What to watch
2029 (27)
January 2029 (5)
PumitamigPhase 2/3Non-small Cell Lung Cancer
Est. primary completion 2029-01 · NCT06712316 · CT.gov ↗
What to watch
deucravacitinib · SotyktuPhase 3Plaque Psoriasis
Est. primary completion 2029-01-01 · NCT04772079 · CT.gov ↗
What to watch
Nivolumab + PumitamigPhase 1/2Advanced Solid Tumors
Est. primary completion 2029-01-04 · NCT06697197 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2/3Urothelial Cancer
Est. primary completion 2029-01-26 · NCT07106762 · CT.gov ↗
What to watch
NivolumabPhase 2Rhabdoid Tumor
Est. primary completion 2029-01-31 · NCT06622941 · CT.gov ↗
What to watch
March 2029 (2)
Est. primary completion 2029-03-03 · NCT07686263 · CT.gov ↗
What to watch
Iberdomide · ZenbexusPhase 3Multiple Myeloma
Est. primary completion 2029-03-15 · NCT05827016 · CT.gov ↗
What to watch
April 2029 (2)
PumitamigPhase 3Extensive-stage Small-cell Lung Cancer
Est. primary completion 2029-04 · NCT06712355 · CT.gov ↗
What to watch
Pumitamig + BMS-986525Phase 1/2Relapsed/Refractory Small Cell Lung Cancer
Est. primary completion 2029-04-23 · NCT07325136 · CT.gov ↗
What to watch
May 2029 (1)
NavlimetostatPhase 2/3Pancreatic Ductal Adenocarcinoma
Est. primary completion 2029-05-03 · NCT07076121 · CT.gov ↗
What to watch
June 2029 (1)
Xanomeline/trospium chloride · CobenfyPhase 3Alzheimer Disease, Agitation
Est. primary completion 2029-06-22 · NCT06937229 · CT.gov ↗
What to watch
July 2029 (2)
Mavacamten · CamzyosPhase 3Non-obstructive Hypertrophic Cardiomyopathy
Est. primary completion 2029-07-21 · NCT07940777 · CT.gov ↗
What to watch
NivolumabPhase 2Richter's Transformation
Est. primary completion 2029-07-31 · NCT06936943 · CT.gov ↗
What to watch
August 2029 (4)
PumitamigPhase 1/2Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Est. primary completion 2029-08 · NCT06827236 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3Irritability Associated With Autism Spectrum Disorder
Est. primary completion 2029-08-06 · NCT07284745 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3Irritability Associated With Autism Spectrum Disorder
Est. primary completion 2029-08-06 · NCT07285798 · CT.gov ↗
What to watch
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
October 2029 (2)
deucravacitinib · SotyktuPhase 3Plaque Psoriasis
Est. primary completion 2029-10-12 · NCT06979453 · CT.gov ↗
What to watch
Pumitamig + IpilimumabPhase 1/2Hepatocellular Carcinoma (HCC)
Est. primary completion 2029-10-15 · NCT07291076 · CT.gov ↗
What to watch
November 2029 (1)
Pumitamig + IpilimumabPhase 1/2Advanced Renal Cell Carcinoma (RCC)
Est. primary completion 2029-11-28 · NCT07293351 · CT.gov ↗
What to watch
December 2029 (7)
Izalontamab brengitecanPhase 2/3Non-squamous Non-small Cell Lung Cancer
Est. primary completion 2029-12 · NCT07739186 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2/3Squamous Non-small-cell Lung Cancer
Est. primary completion 2029-12 · NCT07739199 · CT.gov ↗
What to watch
PumitamigPhase 3Breast Neoplasms
Est. primary completion 2029-12 · NCT07173751 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Extensive-stage Small-cell Lung Cancer
Est. primary completion 2029-12 · NCT07502300 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Triple-Negative Breast Cancer (TNBC)
Est. primary completion 2029-12 · NCT07729956 · CT.gov ↗
What to watch
Est. primary completion 2029-12-18 · NCT07288567 · CT.gov ↗
What to watch
BMS-986548Phase 1/2Advanced Solid Malignancies
Est. primary completion 2029-12-29 · NCT07939815 · CT.gov ↗
What to watch
2030 (13)
February 2030 (1)
PumitamigPhase 2/3Untreated, Unresectable, or Metastatic Colorectal Cancer
Est. primary completion 2030-02-02 · NCT07221357 · CT.gov ↗
What to watch
March 2030 (2)
deucravacitinib · SotyktuPhase 3Juvenile Psoriatic Arthritis
Est. primary completion 2030-03-06 · NCT06869551 · CT.gov ↗
What to watch
Xanomeline/trospium chloride · CobenfyPhase 3Schizophrenia, Autism-Related Irritability
Est. primary completion 2030-03-08 · NCT07424404 · CT.gov ↗
What to watch
April 2030 (1)
AfimetoranPhase 2/3Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
Est. primary completion 2030-04 · NCT07881120 · CT.gov ↗
What to watch
May 2030 (1)
Zolacabtagene autoleucelPhase 2Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
Est. primary completion 2030-05-06 · NCT07603557 · CT.gov ↗
What to watch
June 2030 (1)
RYZ801Phase 1/2Hepatocellular Carcinoma (HCC)
Est. primary completion 2030-06 · NCT06726161 · CT.gov ↗
What to watch
July 2030 (1)
Nivolumab + RelatlimabPhase 3Non-small Cell Lung Cancer
Est. primary completion 2030-07-30 · NCT06561386 · CT.gov ↗
What to watch
September 2030 (1)
PumitamigPhase 3Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2030-09-18 · NCT07361497 · CT.gov ↗
What to watch
October 2030 (1)
deucravacitinib · SotyktuPhase 3Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis
Est. primary completion 2030-10-31 · NCT07791199 · CT.gov ↗
What to watch
November 2030 (1)
PumitamigPhase 2/3Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Est. primary completion 2030-11-08 · NCT07221149 · CT.gov ↗
What to watch
December 2030 (3)
PumitamigPhase 1/2Metastatic Colorectal Cancer
Est. primary completion 2030-12 · NCT07079631 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 2Nasopharyngeal Carcinoma (NPC)
Est. primary completion 2030-12 · NCT07797881 · CT.gov ↗
What to watch
Izalontamab brengitecanPhase 3Non-small Cell Lung Cancer Stage III
Est. primary completion 2030-12 · NCT07640789 · CT.gov ↗
What to watch
2031 (7)
January 2031 (1)
deucravacitinib · SotyktuPhase 3Plaque Psoriasis
Est. primary completion 2031-01-16 · NCT07116967 · CT.gov ↗
What to watch
February 2031 (1)
Nivolumab + Pumitamig + Izalontamab brengitecanPhase 1/2Lung Cancer, Breast Cancer
Est. primary completion 2031-02-26 · NCT06618287 · CT.gov ↗
What to watch
April 2031 (1)
ozanimod · ZeposiaPhase 3Multiple Sclerosis, Relapsing-Remitting
Est. primary completion 2031-04-11 · NCT06408259 · CT.gov ↗
What to watch
August 2031 (2)
Nab-paclitaxel + NavlimetostatPhase 2/3Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Est. primary completion 2031-08-12 · NCT07063745 · CT.gov ↗
What to watch
Nivolumab + Pumitamig + ImzokitugPhase 1/2Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer …
Est. primary completion 2031-08-31 · NCT04895709 · CT.gov ↗
What to watch
October 2031 (1)
PumitamigPhase 3Non-Small Cell Lung Cancer (NSCLC)
Est. primary completion 2031-10-14 · NCT07361510 · CT.gov ↗
What to watch
December 2031 (1)
Izalontamab brengitecanPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2031-12-30 · NCT07680790 · CT.gov ↗
What to watch
2032 (3)
July 2032 (1)
ozanimod · ZeposiaPhase 2/3Colitis, Ulcerative
Est. primary completion 2032-07-12 · NCT05076175 · CT.gov ↗
What to watch
November 2032 (1)
DanicamtivPhase 3Symptomatic Genetic Dilated Cardiomyopathy (DCM)
Est. primary completion 2032-11 · NCT07771465 · CT.gov ↗
What to watch
December 2032 (1)
Izalontamab brengitecanPhase 2/3Non-small Cell Lung Cancer
Est. primary completion 2032-12 · NCT07642024 · CT.gov ↗
What to watch
2033 (1)
December 2033 (1)
Izalontamab brengitecanPhase 3Nasopharyngeal Carcinoma (NPC)
Est. primary completion 2033-12 · NCT07783321 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(27)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

13 May 2027FDA action datemezigdomideMezigdomide NDA PDUFA target action date
US, FDA · Bristol-Myers Squibb · Source ↗
27 May 2027FDA action dateobexelimabObexelimab BLA PDUFA target action date
US, FDA · Zenas BioPharma · Source ↗

Recent

12 October 2026Topline resultRYZ101Phase 3 ACTION-1 (NCT05477576) interim analysis of RYZ101 met its primary endpoint of PFS
Bristol Myers Squibb (RayzeBio) · Source ↗
8 October 2026Topline resultIberdomidePhase 3 EXCALIBER-RRMM (NCT04975997): iberdomide + daratumumab + dexamethasone improved PFS versus DVd
Bristol-Myers Squibb · Source ↗
October 2026Topline resultBMS-986278Phase III ALOFT-IPF topline: FVC primary endpoint met at 60 mg
9 September 2026Topline resultAfimetoranGlobal Phase 2 of afimetoran in systemic lupus erythematosus met its primary endpoint
Beeline Medicines · Source ↗
8 September 2026Topline resultarlocabtagene autoleucelRegistrational Phase 2 QUINTESSENTIAL (NCT06297226) met its primary endpoint
Bristol-Myers Squibb · Source ↗
1 September 2026WithdrawalAdagrasib (Krazati)FDA approves voluntary withdrawal of the Krazati colorectal cancer indication after KRYSTAL-10 (NCT04793958)
US, FDA · Bristol-Myers Squibb Company · Source ↗
September 2026ApprovalThalidomideFDA updates Boxed Warning on Thalidomide (NDA020785)
US, FDA · FDA · Source ↗
September 2026PresentationTunlucabtagene autoleucelPhase 1 data at IMS 2026: overall response rate 83% in 58 treated patients
13 August 2026ApprovalIberdomideFDA grants accelerated approval to ZENBEXUS (iberdomide) in multiple myeloma
US, FDA · Source ↗
13 August 2026ApprovalIberdomideFDA Boxed Warning on Zenbexus (NDA221075)
US, FDA · FDA · Source ↗
August 2026Filing acceptedobexelimabFDA accepts obexelimab BLA for IgG4-related disease
US, FDA · Zenas BioPharma · Source ↗
13 July 2026Filing acceptedmezigdomideFDA accepts mezigdomide NDA (with carfilzomib and dexamethasone)
US, FDA · Bristol-Myers Squibb · Source ↗

The 12 most recent of 25 past events are shown.

Financial reports

Quarterly & interim (18)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$13.1B$2.4B$9.6B+ $3.0B short-term inv.—$4.2B operating cash flowreport ↗
View 17 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$13.0B$3.0B$8.7B+ $2.3B short-term inv.—$3.4B operating cash flowreport ↗
2026-Q1$11.5B$2.6B$9.6B+ $912M short-term inv.—$1.1B operating cash flowreport ↗
2025-Q4$12.5B$2.6B$10.7B—report ↗
2025-Q3$12.2B$2.5B$16.5B+ $776M short-term inv.—$6.3B operating cash flowreport ↗
2025-Q2$12.3B$2.6B$13.6B+ $1.0B short-term inv.—$3.9B operating cash flowreport ↗
2025-Q1$11.2B$2.3B$11.8B+ $907M short-term inv.—$2.0B operating cash flowreport ↗
2024-Q4$12.3B$3.2B$10.9B—report ↗
2024-Q3$11.9B$2.4B$8.1B+ $204M short-term inv.—$5.6B operating cash flowreport ↗
2024-Q2$12.2B$2.9B$6.7B+ $360M short-term inv.—$2.3B operating cash flowreport ↗
2024-Q1$11.9B$2.7B$9.3B+ $340M short-term inv.$11.9B$2.8B operating cash flowreport ↗
2023-Q3$11.0B$2.2B$7.6B+ $171M short-term inv.—$4.8B operating cash flowreport ↗
2023-Q2$11.2B$2.3B$8.4B+ $358M short-term inv.—$1.9B operating cash flowreport ↗
2023-Q1$11.3B$2.3B$9.0B+ $274M short-term inv.—$3.0B operating cash flowreport ↗
2022-Q3$11.2B$2.4B$8.0B+ $1.3B short-term inv.—$3.7B operating cash flowreport ↗
2022-Q2$11.9B$2.3B$11.0B+ $2.5B short-term inv.—$2.3B operating cash flowreport ↗
2022-Q1$11.6B$2.3B$12.6B+ $2.6B short-term inv.—$3.8B operating cash flowreport ↗
2021-Q3$11.6B$3.3B$13.9B+ $2.1B short-term inv.—$5.3B operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$48.2B$10.0B$10.7B+ $464M short-term inv.—$14.2B operating cash flowreport ↗

Bristol Myers Squibb reported full-year 2025 revenue of $48,194M, relatively flat YoY on a reported basis (down 1% Ex-FX), and R&D spend of $9,951M, down 11% YoY on a GAAP basis. Cash and cash equivalents were $10,209M (cash, cash equivalents and marketable debt securities of $11,069M), while GAAP net income attributable to BMS was $7,054M versus a net loss of $8,948M in 2024.

Growth Portfolio revenues rose 17% to $26.4B, while Legacy Portfolio revenues declined 15% to $21.8B. For 2026, the company guided to revenues of $46.0B-$47.5B and non-GAAP diluted EPS of $6.05-$6.35, with Eliquis worldwide revenue growth expected at 10%-15%. Pipeline highlights included positive Phase 3 SCOUT-HCM data for Camzyos, FDA priority review for Opdivo in classical Hodgkin lymphoma, FDA and European Commission approvals for Breyanzi, and a decision to stop the Phase 3 Librexia ACS trial of milvexian; the company also announced a Microsoft collaboration on AI-based lung cancer early detection and raised its quarterly dividend to $0.63 per share.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$48.3B$11.2B$10.9B+ $513M short-term inv.—$15.2B operating cash flowreport ↗
2023-FY$45.0B$9.3B$12.3B+ $816M short-term inv.—$13.9B operating cash flowreport ↗
2022-FY$46.2B$9.5B$9.3B+ $130M short-term inv.—$13.1B operating cash flowreport ↗
2021-FY$46.4B$11.4B$14.3B+ $3.0B short-term inv.—$16.2B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 5 sales ($2.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-05Haller Julia A · directorOpen-market sale3,800$63.31$241KForm 4
2026-11-03Lenkowsky Adam · EVP, Chief Commercial OfficerOption exercise7,522——Form 4
2026-11-03Lenkowsky Adam · EVP, Chief Commercial OfficerTax withholding3,848$61.71$237KForm 4
2026-11-03Lenkowsky Adam · EVP, Chief Commercial OfficerOption exercise (derivative)7,522——Form 4
2026-11-01Meyers Gregory Scott · EVP, Chief Digital & Tech Off.Option exercise6,281——Form 4
2026-11-01Shanahan Karin · EVP, Chief Supply Chain & OpsOption exercise6,281——Form 4
2026-11-01BOERNER CHRISTOPHER S. · director, Chief Executive OfficerOption exercise2,964——Form 4
2026-11-01Meyers Gregory Scott · EVP, Chief Digital & Tech Off.Tax withholding2,665$62.48$167KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 2,496 reporting institutions held 1607.6M shares ($92.6B, 78.5% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.171,682,888$10.4B
2VANGUARD CAPITAL MANAGEMENT LLC132,320,240$8.0B
3STATE STREET CORP98,564,914$6.0B
4JPMORGAN CHASE & CO92,475,194$5.5B
5CHARLES SCHWAB INVESTMENT MANAGEMENT INC61,115,373$3.7B
6GEODE CAPITAL MANAGEMENT, LLC55,286,174$3.3B
7VANGUARD PORTFOLIO MANAGEMENT LLC46,230,155$2.8B
8BANK OF AMERICA CORP /DE/32,586,981$2.0B
9AQR CAPITAL MANAGEMENT LLC29,631,105$1.8B
10MORGAN STANLEY29,198,554$1.8B
11AMERIPRISE FINANCIAL INC26,470,718$1.6B
12PRIMECAP MANAGEMENT CO/CA/24,985,149$1.5B
13NORTHERN TRUST CORP24,758,771$1.5B
14Bank of New York Mellon Corp23,301,337$1.4B
15UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC22,719,320$1.4B